Pediatric Vaccines Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Pediatric Vaccines Market Size Analysis

Global Pediatric Vaccines Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Monovalent
    1. By Value
  3. Multivalent
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Live Attenuated Vaccines
    1. By Value
  3. Inactivated Vaccines
    1. By Value
  4. Subunit Vaccines
    1. By Value
  5. Toxoid Vaccines
    1. By Value
  6. Conjugate Vaccines
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Infectious Disease
    1. By Value
  3. Cancer
    1. By Value
  4. Allergy
    1. By Value
  5. Pneumococcal Diseases
    1. By Value
  6. Influenza
    1. By Value
  7. Measles, Mumps, and Rubella (MMR)
    1. By Value
  8. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Monovalent
    1. By Value
  3. Multivalent
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Live Attenuated Vaccines
    1. By Value
  3. Inactivated Vaccines
    1. By Value
  4. Subunit Vaccines
    1. By Value
  5. Toxoid Vaccines
    1. By Value
  6. Conjugate Vaccines
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Infectious Disease
    1. By Value
  3. Cancer
    1. By Value
  4. Allergy
    1. By Value
  5. Pneumococcal Diseases
    1. By Value
  6. Influenza
    1. By Value
  7. Measles, Mumps, and Rubella (MMR)
    1. By Value
  8. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Monovalent
    1. By Value
  3. Multivalent
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Live Attenuated Vaccines
    1. By Value
  3. Inactivated Vaccines
    1. By Value
  4. Subunit Vaccines
    1. By Value
  5. Toxoid Vaccines
    1. By Value
  6. Conjugate Vaccines
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Infectious Disease
    1. By Value
  3. Cancer
    1. By Value
  4. Allergy
    1. By Value
  5. Pneumococcal Diseases
    1. By Value
  6. Influenza
    1. By Value
  7. Measles, Mumps, and Rubella (MMR)
    1. By Value
  8. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Monovalent
    1. By Value
  3. Multivalent
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Live Attenuated Vaccines
    1. By Value
  3. Inactivated Vaccines
    1. By Value
  4. Subunit Vaccines
    1. By Value
  5. Toxoid Vaccines
    1. By Value
  6. Conjugate Vaccines
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Infectious Disease
    1. By Value
  3. Cancer
    1. By Value
  4. Allergy
    1. By Value
  5. Pneumococcal Diseases
    1. By Value
  6. Influenza
    1. By Value
  7. Measles, Mumps, and Rubella (MMR)
    1. By Value
  8. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Monovalent
  1. By Value
3. Multivalent
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Live Attenuated Vaccines
  1. By Value
3. Inactivated Vaccines
  1. By Value
4. Subunit Vaccines
  1. By Value
5. Toxoid Vaccines
  1. By Value
6. Conjugate Vaccines
  1. By Value
7. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Infectious Disease
  1. By Value
3. Cancer
  1. By Value
4. Allergy
  1. By Value
5. Pneumococcal Diseases
  1. By Value
6. Influenza
  1. By Value
7. Measles, Mumps, and Rubella (MMR)
  1. By Value
8. Others
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Monovalent
    1. By Value
  3. Multivalent
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Live Attenuated Vaccines
    1. By Value
  3. Inactivated Vaccines
    1. By Value
  4. Subunit Vaccines
    1. By Value
  5. Toxoid Vaccines
    1. By Value
  6. Conjugate Vaccines
    1. By Value
  7. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Infectious Disease
    1. By Value
  3. Cancer
    1. By Value
  4. Allergy
    1. By Value
  5. Pneumococcal Diseases
    1. By Value
  6. Influenza
    1. By Value
  7. Measles, Mumps, and Rubella (MMR)
    1. By Value
  8. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Pediatric Vaccines Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Sanofi
GSK plc
Merck & Co., Inc.
AstraZeneca
Johnson & Johnson Services Inc.
Moderna, Inc.
BioNTech SE
Novavax, Inc.
Valneva SE
Daiichi Sankyo Company Limited
Takeda Pharmaceutical Company Limited
Serum Institute of India Pvt. Ltd.
Bharat Biotech
Indian Immunologicals Ltd.
Zydus Group
Sinovac
Biological E Limited

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment